Q1 Earnings Estimate for MREO Issued By Leerink Partnrs

Mereo BioPharma Group plc (NASDAQ:MREO) – Equities research analysts at Leerink Partnrs issued their Q1 2025 earnings per share (EPS) estimates for shares of Mereo BioPharma Group in a report issued on Wednesday, March 26th. Leerink Partnrs analyst J. Schwartz forecasts that the company will post earnings per share of $0.07 for the quarter. The consensus estimate for Mereo BioPharma Group’s current full-year earnings is ($0.03) per share. Leerink Partnrs also issued estimates for Mereo BioPharma Group’s Q2 2025 earnings at $0.05 EPS, Q3 2025 earnings at ($0.02) EPS, Q4 2025 earnings at ($0.02) EPS, FY2025 earnings at $0.08 EPS and FY2026 earnings at ($0.03) EPS.

A number of other brokerages have also recently issued reports on MREO. JPMorgan Chase & Co. initiated coverage on Mereo BioPharma Group in a research note on Thursday, March 27th. They set an “overweight” rating and a $7.00 price objective for the company. Needham & Company LLC reiterated a “buy” rating and issued a $7.00 price target on shares of Mereo BioPharma Group in a research note on Wednesday, March 26th. Jefferies Financial Group initiated coverage on shares of Mereo BioPharma Group in a research report on Friday, December 6th. They set a “buy” rating and a $7.00 price objective on the stock. Cantor Fitzgerald reissued an “overweight” rating and issued a $7.00 target price on shares of Mereo BioPharma Group in a report on Tuesday, March 18th. Finally, Lifesci Capital initiated coverage on Mereo BioPharma Group in a research note on Tuesday, December 24th. They set an “outperform” rating and a $10.00 price target for the company. Six equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $7.71.

Mereo BioPharma Group Stock Performance

Shares of NASDAQ MREO opened at $2.25 on Monday. The company has a 50 day simple moving average of $2.71 and a two-hundred day simple moving average of $3.46. Mereo BioPharma Group has a fifty-two week low of $2.16 and a fifty-two week high of $5.02. The company has a market capitalization of $349.08 million, a price-to-earnings ratio of -37.50 and a beta of 1.03.

Mereo BioPharma Group (NASDAQ:MREO) last announced its earnings results on Wednesday, March 26th. The company reported ($0.01) EPS for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.03).

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new position in Mereo BioPharma Group during the fourth quarter worth $3,377,000. Woodline Partners LP purchased a new position in Mereo BioPharma Group during the 4th quarter valued at $2,166,000. Tema Etfs LLC bought a new position in Mereo BioPharma Group in the 4th quarter valued at $3,117,000. Janus Henderson Group PLC increased its stake in Mereo BioPharma Group by 38.7% in the fourth quarter. Janus Henderson Group PLC now owns 17,122,563 shares of the company’s stock worth $59,843,000 after purchasing an additional 4,776,697 shares during the period. Finally, Graham Capital Management L.P. lifted its holdings in Mereo BioPharma Group by 74.7% during the 4th quarter. Graham Capital Management L.P. now owns 22,189 shares of the company’s stock valued at $78,000 after buying an additional 9,490 shares in the last quarter. 62.83% of the stock is owned by hedge funds and other institutional investors.

Mereo BioPharma Group Company Profile

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors.